Clinical Trial Results: Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy [Phase 2]

View source ↗

Summary

Phase 2 results for APX3330 in diabetic retinopathy and diabetic macular edema have been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema
• Diabetic Retinopathy

Drugs mentioned

• APX3330

Snippet

Sponsor: Ocuphire Pharma, Inc. | Conditions: Diabetic Retinopathy, Diabetic Macular Edema | Phase 2 | Status: COMPLETED | Results posted: 2026-06-08